View More Recent Stories
-
Arcus Biosciences (RCUS) PT Lowered to $23 at BofA Securities
-
Arcus Biosciences (RCUS) PT Lowered to $25 at Barclays
-
Cantor Fitzgerald Reiterates Overweight Rating on Arcus Biosciences (RCUS)
-
Arcus Biosciences (RCUS) PT Lowered to $44 at Truist Securities


